Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML
Key facts
- Who runs it
- Washington University School of Medicine
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 30 Jun 2023
- Expected to end
- 31 Jul 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Cytokine induced memory-like NK cells
- Fludarabine
- Ara-C
- G-CSF
- Interleukin-2
- Leukapheresis
- Record updated
- 4 April 2023
- Why it stopped
- Principal investigator decided not to move forward with the study.
Who can take part
- Age
- 1 year to 21 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Refractory AML without complete remission (CR) after induction therapy (primary induction failure) or relapsed AML after obtaining a CR. Disease defined by one of the following:; *≥ 5% blasts in the bone marrow (M2/M3 bone marrow), with or without extramedullary disease; *absolute blast count greater than 1,000 per microliter in the peripheral blood with or without extramedullary disease
- Age requirement for pediatric cohort: 1-21 years of age
- Available HLA-haploidentical donor that meets the following criteria:; Related donor (parent, sibling, offspring, or offspring of sibling); At least 18 years of age; HLA-haploidentical donor/recipient match by at least Class I serologic typing at the A\&B locus; In general, good health and medically able to tolerate leukapheresis required for harvesting the NK cells for this study; Negative for hepatitis, HTLV, and HIV on donor viral screen; Not pregnant; Voluntary written consent to participate in this study
- Patients with known CNS involvement with AML are eligible provided that they have been treated and CSF is clear for at least 2 weeks prior to enrollment into the study. CNS therapy (chemotherapy or radiation) should continue as medically indicated during the study treatment
- Karnofsky/Lansky performance status > 50 %
- Adequate organ function as defined below:; Total bilirubin < 2 mg/dL; AST(SGOT)/ALT(SGPT) < 3.0 x upper limit of normal (ULN); Creatinine within normal institutional limits OR creatinine clearance > 50 mL/min/1.73 m2 by Schwartz formula or GFR (See Appendix B); Oxygen saturation ≥90% on room air; Ejection fraction ≥35%
- Able to be off corticosteroids and any other immune suppressive medications beginning on Day -3 and continuing until 30 days after the infusion of the CIML NK cells. However, use of low-level corticosteroids is permitted if deemed medically necessary. Low-level corticosteroid use is defined as 10mg or less of prednisone (or equivalent for other steroids) per day
- Women of childbearing potential must have a negative pregnancy test within 28 days prior to study registration. Female and male patients (along with their female partners) must agree to use two forms of acceptable contraception, including one barrier method, during participation in the study and throughout the DLT evaluation period
- Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable)
Who cannot take part
- Relapsed after allogeneic transplantation
- Received any investigational drugs within the 14 days prior to the first dose of fludarabine
- Patients with any of the following diagnoses:; Down's syndrome; Acute promyelocytic leukemia (APL); Juvenile myelomonocytic leukemia (JMML)
- Uncontrolled bacterial or viral infections, or known HIV, Hepatitis B or C infection
- Known hypersensitivity to one or more of the study agents
- Circulating blast count >30,000/µL by morphology or flow cytometry (cytoreductive therapies including leukapheresis or hydroxyurea are allowed)
- Isolated extramedullary relapse
- Pregnant
About the trial
What the trial wants to find out
This phase 2 clinical trial investigates the effectiveness of cytokine-induced memory-like natural killer (CIML NK) cells in combination with FLAG chemotherapy as a treatment for refractory or relapsed AML. Previous studies in adults with AML sowed successful induction of remission and a previous phase 1 study demonstrated that CIML NK cells can be used safely in pediatric patients. This phase 2 study uses FLAG chemotherapy to lower leukemic burden and suppress the recipient's immune system to provide an optimal environment for CIML NK cell expansion and anti-leukemic activity.
The 2 groups in the trial
- Recipient: FLAG + CIML NK Cells + IL-2Treatment being tested
-The recipient will begin a chemotherapy regimen of fludarabine, cytarabine and GCSF starting on Day -7. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20 L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. CIML NK cells will be infused at maximum cell dose of 10 x 106/kg. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
Treatment: Cytokine induced memory-like NK cells, Fludarabine, Ara-C, G-CSF, and Interleukin-2
- Donor:Other group
-On Day -1 (one day before the planned NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard apheresis over 4-5 hours (with a target volume of at least 20 L) from the identified haploidentical donor. The apheresis procedure will be done as per standard institutional procedures (which may include placement of a central line if necessary). If the goal minimum NK cell dose will not be met based on the initial assessment of the leukapheresis product, a second collection/procedure may be performed.
Treatment: Leukapheresis
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed AML
- Record updated
- 4 April 2023